Get started
Author

Emma Tyas

ORCID: 0009-0002-6984-1425
Observed ORCID: 0009-0002-6984-1425
OpenAlex ID: A5042090419
Matching-Adjusted Indirect Comparison of Osilodrostat Versus Metyrapone for the Treatment of Cushing’s Syndrome
2025 · Conor Hickey, Beatrice Gueron, et al. · Advances in Therapy · 4
Real‐world outcomes of patients with relapsed/refractory large B‐cell lymphoma receiving second‐line therapy in England
2024 · Christopher P. Fox, William Townsend, et al. · eJHaem · 3
PDF
A Cost-Utility Analysis of Add-On Cannabidiol Versus Usual Care Alone for the Treatment of Seizures Associated with Tuberous Sclerosis Complex in England and Wales
2024 · Colin Burke, Catriona Crossan, et al. · PharmacoEconomics - Open · 2
PDF
Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS
2024 · Alicia K. Morgans, Jamie Partridge Grossman, et al. · Journal of Managed Care & Specialty Pharmacy · 1
PDF
Rate of hospitalization and length of hospital stay during and post docetaxel for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS.
2024 · Alicia K. Morgans, Martin Boegemann, et al. · Journal of Clinical Oncology · 1
PDF
Comparative Efficacy and Safety of Osilodrostat Vs Metyrapone for the Treatment of Cushing's Syndrome - a Matching-Adjusted Indirect Treatment Comparison
2023 · Emma Tyas, Conor Hickey, et al. · Endocrine Abstracts · 1
Msr16 the Impact of Different Time-varying Network Meta-analysis Methods to Assess Talazoparib + Enzalutamide Versus Olaparib + Abiraterone in Metastatic Castration-resistant Prostate Cancer
2026 · Melissa Kirker, Neo Su, et al. · Value in Health
Ip73-04 Impact of Anemia and Its Management on Quality of Life in Metastatic Castration‑resistant Prostate Cancer Patients Treated With Talazoparib Plus Enzalutamide
2026 · Neal D. Shore, Melissa Kirker, et al. · The Journal of Urology
Comparative effectiveness of atogepant and rimegepant for migraine prevention in Japanese patients: an anchored matching-adjusted indirect comparison
2025 · Tsubasa Takizawa, Gina Ahmadyar, et al. · Expert Review of Neurotherapeutics
PDF
CO191 Prognostic Factor Evaluation for Clinical Outcomes in HER2-Mutant NSCLC
2025 · Heiko Zettl, Lorenz Uhlmann, et al. · Value in Health
CO174 Matching-Adjusted Indirect Comparison of Isatuximab-Bortezomib-Lenalidomide-Dexamethasone (IVRd) with Daratumumab-Lenalidomide-Dexamethasone (DRd) in Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplant
2025 · Feng Lin, Gaye Siliman, et al. · Value in Health
MSR62 Keeping With the Times: Emerging Methods for More Precise Survival Estimates to Inform Cost-Effectiveness Analysis
2025 · Yu-Heng Liu, Ioana Gulas, et al. · Value in Health
Comparative efficacy and safety of osilodrostat vs metyrapone for the treatment of Cushing's syndrome - a matching-adjusted indirect comparison using LINC-3 and LINC-4
2024 · Rosario Pivonello, Beatrice Gueron, et al. · Endocrine Abstracts
Works count: 13
Citation count: 12
H-index: 2
I10-index:
Year
Topic
Type